Group 1 - The company expects to achieve an annual revenue of approximately 7.7 billion to 7.8 billion RMB, representing a year-on-year growth of 16.0% to 17.6% [2][6] - The projected net profit attributable to shareholders is between 1.3 billion to 1.4 billion RMB, showing a significant year-on-year increase of 80.1% to 93.9% [2][6] - Adjusted net profit is estimated to be between 1.25 billion to 1.35 billion RMB, with a year-on-year growth of 24.1% to 34.1% [2][6] Group 2 - The growth in performance is primarily attributed to increased revenue from innovative drugs, licensing income, and net gains from the fair value of the investment portfolio [2][6] - Despite the positive earnings forecast, the company's stock price declined by 5.31% to 12.31 HKD per share, with a market capitalization of 31.95 billion HKD as of February 26 [7] - Industry insiders remain optimistic about the company's development, highlighting its focus on neuroscience and oncology, as well as significant achievements in innovative drug research and commercialization [7] Group 3 - Since 2025, the company has established multiple licensing agreements with pharmaceutical firms such as AbbVie, NextCure, and Boehringer Ingelheim, contributing to accelerated growth [3][7] - In February 2026, the company announced a payment of 40 million USD from AbbVie for the SIM0500 project, along with potential milestone payments of up to 1.055 billion USD [3][7] - A report from Guotai Junan Securities indicates that the company's ongoing innovation transformation and international expansion of its product pipeline have led to an upward revision of revenue and profit forecasts for 2026 [3][7]
先声药业发布盈喜公告，股价竟跌超5%